Regulatory Milestone for Oral Obesity Drugs Boosts Viking Therapeutics Shares

Shares of Viking Therapeutics gained approximately 2.9% to $36.42 following a pivotal regulatory decision that is reshaping the market for weight-loss medications. The catalyst was the U.S. Food and Drug Administration (FDA) granting its first-ever approval for an oral version of Novo Nordisk’s Wegovy. This development is viewed less as a direct company announcement from Viking and more as a significant positive signal for the entire oral GLP-1 therapy sector.

A Clear Path Forward for Oral Therapies

The FDA’s approval of oral Wegovy (semaglutid 25 mg) for chronic weight management represents a long-anticipated validation for the industry. It formally confirms that tablet-based GLP-1 treatments are both commercially viable and meet regulatory standards, setting a clear precedent for other drug candidates.

Key details of the approval include:
* Active Ingredient: Semaglutid 25 mg (oral Wegovy formulation)
* Average Weight Loss in Phase 3 (OASIS-4) Trial: Approximately 14% to 16.6%
* Study Duration: 64 to 71 weeks
* Planned U.S. Launch: January 2026
* Introductory Price: $149 per month for eligible patients

The news propelled Novo Nordisk’s stock upward by more than 8%. Other developers in the obesity segment also advanced, with Structure Therapeutics rising about 6% and Viking gaining nearly 3%. Investors are increasingly betting that the addressable market for oral obesity treatments will expand substantially.

For Viking, the decision carries a dual implication. While Novo Nordisk secures a “first-mover” advantage in the U.S. oral segment, the regulatory pathway for oral GLP-1 agonists is now demonstrably established. This reduces the perceived approval risk for subsequent candidates. Viking’s lead drug, VK2735, is seen as a potentially competitive oral GLP-1 candidate, and future comparisons of its data against the now-confirmed Wegovy benchmarks are expected to intensify.

Should investors sell immediately? Or is it worth buying Viking Therapeutics?

Positioning in a Multi-Billion Dollar Market

This regulatory event occurs as the global GLP-1 market is projected to surpass $100 billion by 2030. Injectable formulations currently dominate, but oral options are considered the next major growth frontier, largely due to patient convenience and potential for improved adherence.

Market experts categorize Viking as a relevant player in this “second wave” of GLP-1 development. While Novo Nordisk and Eli Lilly command the current market, smaller biotech firms like Viking are focusing on differentiated profiles, such as enhanced efficacy or tolerability. The FDA’s smooth approval of the oral formulation is interpreted by observers as a fundamentally positive indicator for the broader pipeline in this space.

Analysts note that despite Novo’s lead, the sheer size of the obesity treatment segment leaves ample room for multiple successful products. Viking’s solid financial position and clinical progress to date are cited as reasons why its shares reacted steadily within the sector and were able to capitalize on the buoyant market sentiment.

The Road to 2026

For Viking, 2026 is shaping up to be a critical year, as the competitive landscape for oral GLP-1 drugs becomes more defined. With the U.S. launch of oral Wegovy set for January 2026, the benchmark for efficacy and commercial success is now clearly established at a weight loss range of roughly 14% to 16%. Consequently, investor focus will shift to Viking’s upcoming clinical data for VK2735, which will be measured directly against this new standard.

From a technical perspective, the share price increase to $36.42 reflects sustained interest from both institutional and retail investors. Whether the stock can maintain this level in upcoming trading sessions will likely depend on the broader sentiment in the GLP-1 sector and further details regarding the competitive launch timeline in early 2026.